Dana-Farber Cancer Institute
J

Waldenström Macroglobulinemia: Diagnostic criteria, Why Not Treat Everybody at Diagnosis & Somatic Mutations in MYD88 and CXCR4

By Dana-Farber Cancer Institute FEATURING Jorge Castillo
By Dana-Farber Cancer Institute FEATURING Jorge Castillo
638 views
October 11, 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Related Content

AUTOPLAY
08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
10:49
Monia Marchetti

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

10:06
ASCO 2022 Conference Coverage

ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as Primary Therapy fo…

Feat. J. Abeykoon
08:19
ASH 2022 Conference Coverage

ASH 2022 Results From the Phase 1/2 BRUIN Study: Safety & Tolera…

Feat. N. Shah
31:51
Indy Hematology Review

Managing Newly Diagnosed MM in 2023

Feat. S. Usmani
03:42
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "BELLWAVE-003 - A Phase 2 Dose Escalation,…

Feat. G. Perini
11:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Ibrutinib and Venetoclax in Symptomatic, Tr…

Feat. J. Castillo
24:53
Indy Hematology Review

Emerging and Current Treatment of Amyloidosis and Waldenstrom’s Macr…

Feat. M. Gertz
28:28
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Manage Waldenstrom’s Macroglobulinemia in the…

Feat. S. Treon
03:40
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Long-Term Safety With ≥12 Months of Pirto…

Feat. C. Coombs
08:34
ASH 2022 Conference Coverage

ASH 2022: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-C…

Feat. M. Shadman
21:29
Indy Hematology Review

Indy Hematology Review 2023: Emerging Therapies in Hematologic Malig…

Feat. R. Birhiray
25:45
Indy Hematology Review

Managing Newly Diagnosed Multiple Myeloma and Waldenstrom's Mac…

Feat. S. Usmani
51:44
PleXus Communications

Management of Waldenstrom's Macroglobulinemia in the Era of Tar…

Feat. S. Treon
23:36
MyCancerHaven

Experts Discuss the Basics of Diagnosis and Treatment of Waldenstrom…

Feat. R. Vij, J. Castillo